Cerebral Vasospasm (CVS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Cerebral Vasospasm (CVS) Market Outlook

Thelansis’s “Cerebral Vasospasm (CVS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cerebral Vasospasm treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cerebral Vasospasm (CVS) Overview

Cerebral Vasospasm (CVS) is characterized by the narrowing of blood vessels in the brain, resulting in decreased blood flow and subsequent brain tissue damage. The Circle of Willis, located at the base of the brain and connecting its major arteries, is frequently affected. This condition commonly arises following a subarachnoid hemorrhage, which occurs when an aneurysm ruptures, leading to bleeding around the brain. CVS affects approximately 75% of individuals who survive such hemorrhages, although only about 30% experience symptomatic cognitive deficits. Intracranial arterial constriction typically emerges several days after an aneurysm rupture and persists for 2 to 3 weeks. Our research has shown that symptomatic vasospasm is linked to diminished cognitive function and reduced quality of life, though not necessarily to death or severe disability. Delayed cerebral ischemia (DCI) appears to be the most comprehensive and clinically relevant definition for capturing the adverse consequences of vasospasm following subarachnoid hemorrhage. Once diagnosed, treatment options for CVS include elevating blood pressure to enhance brain perfusion and performing angiography. Depending on the severity and location of the vasospasm, physicians may administer medication directly into the affected arteries via angiography or perform balloon angioplasty to widen the narrowed vessels. Cerebral Vasospasm has been estimated to occur in approximately 50% of patients with aneurysmal subarachnoid hemorrhage (aSAH), a condition affecting around 40,000 individuals in North America annually. Symptomatic vasospasm, occurring in 16% of patients, is accompanied by delayed cerebral ischemia in 21%, angiographic vasospasm in 31%, and transcranial Doppler (TCD) spasm in 45% of cases.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: